Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Selected baseline demographic and clinical characteristics of 24 patients with metastatic MITF family translocation renal cell carcinoma treated with an immune checkpoint inhibitor

From: Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders

Characteristics Number of patients Percentage of patients
Sex
 Male 4 20
 Female 20 80
Age, years
 Median 34  
 Range 3–79  
  ≤ 34 11 46
  > 34 13 54
Karnofsky score
  ≤ 80 9 40
  > 80 13 60
Translocation type
 TFE3 21 88
 TFEB 3 12
Common site of metastasis
 Lymph nodes 15 63
 Lung 8 33
 Liver 8 33
 Bone 8 33
Heng score
 0 (favorable) 2 8
 1–2 (intermediate) 18 75
 3–4- 5 (poor) 4 17
First-line therapy
 Sunitinib 15 63
 Pazopanib 4 17
 Sorafenib 1 4
 m-TOR inhibitor 2 8
 High dose IL2 1 4